Back to Search Results
Back to Results
Head and Neck
General Information
Study Name:
Merck 689: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Age Group:
Adult
Protocol Number:
NCT03765918
Background Information:
This study is for patients with newly diagnosed, localized, and advanced Head and Squamous Cell Carcinoma and whose doctor has recommended surgery.
Offered at:
Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital
Eligibility Information
Have histologically confirmed new diagnosis of resectable, non-metastatic, squamous cell carcinoma as assessed by the investigator based on baseline imaging and clinical assessment that is either: Stage III oropharyngeal p16 positive that is T4 (N0-N2), M0 or Stage III or IVA oropharyngeal p16 negative or Stage III or IVA larynx/hypopharynx/oral cavity.
Be eligible for primary surgery based on investigator decision and per local practice. This decision must be validated by members of a multidisciplinary team, including the surgical oncologist, medical oncologist and radiation oncologist.
Additional eligibility in protocol.
Ineligibility Information
Has Stage T4B and/or N3 LA HNSCC and/or distant metastases.
Has cancer outside of the oropharynx, larynx, and hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary HNC
Additional ineligibility in protocol
Contact Information
Contact Name:
Kelly Jeffords, CCRP
Contact Phone:
571-472-0631
Contact Email:
kelly.jeffords@inova.org